AIM ImmunoTech Profit Margin

The latest profit margin for AIM is -15021.05% as of June 2026. That compares with -13360.33% in the prior-year period — down 12.4% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside AIM ImmunoTech's historical trend and sector peers before judging valuation or financial health.

Over the past year, AIM's profit margin moved from -13360.33% to -15021.05% — a 12.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AIM ImmunoTech's valuation or profitability profile.

Against Healthcare companies, AIM currently prints -15021.05% for profit margin, while the sector average sits near 13.89%. That is roughly 108281.1% below the sector mean. Large gaps often invite a closer look at AIM ImmunoTech's growth, margins, and balance sheet.

Profit Margin shows how effectively AIM ImmunoTech converts resources into returns. At -15021.05%, AIM may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -13360.33% in the prior-year period — down 12.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AIM's profit margin (-15021.05%), review year-over-year change from -13360.33%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.